Opko Health Inc. (NASDAQ:OPK) announces the appointment of Jane Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories, effective October 1, 2016.
Ms. Wood is a nationally respected healthcare attorney who has been practicing law for 29 years. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 pathology groups and 350 clinical laboratories. For the past 28 years she has been with the multi-state law firm McDonald Hopkins LLC, where she is a member of the firm’s board of directors. Ms. Wood is a frequent speaker at national and state laboratory and pathology meetings, is a contributor to association publications and is regularly quoted in the national press. Ms. Wood graduated from the Vanderbilt University School of Law.
“We are delighted to welcome Jane to the BioReference Laboratories team. She has a distinguished legal career, having counseled a multitude of pathology practices and clinical laboratories across the country; she is considered one of the leading legal experts in the field. Her diverse experience and insight on matters impacting the diagnostics and laboratory industries will be of great value as we continue to deliver high quality diagnostic services to improve patient care,” said Gregory S. Henderson, M.D., Ph.D., President of BioReference Laboratories. (Original Source)
Shares of Opko Health closed yesterday at $9.89, up $0.14 or 1.44%. OPK has a 1-year high of $10.54 and a 1-year low of $8.71. The stock’s 50-day moving average is $9.75 and its 200-day moving average is $10.05.
On the ratings front, Opko has been the subject of a number of recent research reports. In a report issued on August 16, Jefferies Co. analyst Brandon Couillard reiterated a Hold rating on OPK. Separately, on August 9, J.P. Morgan’s Dana Flanders reiterated a Buy rating on the stock and has a price target of $14.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brandon Couillard and Dana Flanders have a total average return of 12.9% and -5.8% respectively. Couillard has a success rate of 66% and is ranked #169 out of 4143 analysts, while Flanders has a success rate of 33% and is ranked #3136.
Overall, 2 research analysts have assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $18.00 which is 82.0% above where the stock closed yesterday.
OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company. The company is engaged in discovering, developing, commercializing and expertise its novel and proprietary technologies with a focus to provide unmet medical needs through a range of develops solutions to diagnose, treat and prevent various conditions, including molecular diagnostics, point-of-care tests and proprietary pharmaceuticals and vaccines. It operates its business through two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment consists of pharmaceutical research and development operations in Chile, Mexico, Ireland, Israel and Spain.